COMMUNIQUÉS West-GlobeNewswire

-
Eurobio Scientific : RESULTAT DU 1ER SEMESTRE 2024
24/09/2024 -
Eurobio Scientific: RESULTS FOR THE 1ST HALF OF 2024
24/09/2024 -
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines
24/09/2024 -
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
24/09/2024 -
Appointment of Dr. Kalpesh Barot, MD Completes Phase One of ADIA Nutrition’s Medical Division
24/09/2024 -
NeuroOne® Spinal Cord Stimulation Electrode Technology to be Featured at The Business of Pain Conference
24/09/2024 -
AAMI, CTA to Collaborate on AI Standards
24/09/2024 -
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
24/09/2024 -
Lighthouse Autism Center Announces Expansion of ABA Services in Iowa
24/09/2024 -
Georgiamune Announces First Participant Dosed in First-In-Class Phase 1 Healthy Volunteers Trial of GIM-407
24/09/2024 -
Conception Nurseries Launches TrueClones™ X
24/09/2024 -
Tersa Earth and Silica-X Sign MoU to Revolutionize Mining and Waste Management with AI-Powered Biotech and Zero-Waste Solutions
24/09/2024 -
Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
24/09/2024 -
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology – Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference
24/09/2024 -
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
24/09/2024 -
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
24/09/2024 -
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
24/09/2024 -
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
24/09/2024 -
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
24/09/2024
Pages